Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.34 |
| ▸ | JAK2 | O60674 | 13/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611347 | 1.00 | JAK1 (0.34) | JAK1JAK2RETKDREGFR | |
| SCHEMBL16611256 | 0.89 | PIK3CD (0.37) | JAK1JAK2RETKDREGFR | |
| SCHEMBL16611161 | 0.88 | JAK2 (0.39) | JAK1JAK2 | |
| SCHEMBL16610880 | 0.88 | JAK1 (0.34) | JAK1JAK2RETKDREGFR | |
| SCHEMBL16610893 | 0.88 | JAK1 (0.34) | JAK1JAK2RETKDREGFR | |
| SCHEMBL16611254 | 0.88 | JAK1 (0.34) | JAK1JAK2RETKDREGFR | |
| SCHEMBL16611499 | 0.88 | EGFR (0.34) | JAK1JAK2EGFR | |
| SCHEMBL16611397 | 0.87 | JAK2 (0.31) | JAK1JAK2KDREGFR | |
| SCHEMBL16610991 | 0.87 | JAK2 (0.31) | JAK1JAK2KDREGFR | |
| SCHEMBL16611329 | 0.87 | JAK2 (0.31) | JAK1JAK2KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | JAK1 2/4885JAK2 1/4885RET 2202/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | JAK1 2/4885JAK2 1/4885RET 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.